Copyright
©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2365-2372
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Responders (n = 9) | Non-responders (n = 11) | |||
Day 0 | Day 7 | Day 0 | Day 7 | |
Slope | 1.51 [1.31, 1.68] | 1.09 [0.84, 1.23] | 1.52 [1.22, 1.62] | 1.33 [0.86, 1.71] |
P value | 0.018 | 0.511 | ||
TTP | 10.56 [9.33, 12.13] | 12.43 [11.94, 13.94] | 11.02 [8.53, 12.51] | 11.84 [10.15, 13.82] |
P value | 0.003 | 0.247 | ||
AUC | 266.51 [225.38, 296.67] | 156.44 [123.05, 178.91] | 258.14 [191.61, 299.51] | 229.65 [176.10, 269.50] |
P value | 0.001 | 0.322 |
- Citation: Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25(19): 2365-2372
- URL: https://www.wjgnet.com/1007-9327/full/v25/i19/2365.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i19.2365